Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Réglementation et droit · 22/09/20161 min de lecture
Prospective Grant of Exclusive Patent License: Development of an Antibody-Drug Conjugate for Use in PhotoImmunoTherapy
Traduction automatique locale · Langue originale de la source
Résumé
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Summary Information section of this notice to Aspyrian Therapeutics, Inc. ("Aspyrian") located in San Diego, California USA.
Langue originale de la source: Federal Register — All DocumentsOuvrir le communiqué original →